Original ArticleReview of 1027 Patients With Newly Diagnosed Multiple Myeloma
Section snippets
PATIENTS AND METHODS
The records of all patients in whom multiple myeloma, plasmacytic myeloma, plasma cell myeloma, myelomatosis, or Kahler disease was initially diagnosed at the Mayo Clinic in Rochester, Minn, from January 1, 1985, to December 31, 1998, were reviewed. The diagnosis of multiple myeloma was based on the following findings: (1) increased numbers of abnormal, atypical, or immature plasma cells in the bone marrow or histologic proof of plasmacytoma; (2) presence of an M-protein in the serum or urine;
RESULTS
Criteria for the diagnosis of multiple myeloma were fulfilled for 1027 patients seen at the Mayo Clinic in Rochester, Minn, from January 1, 1985, through December 31, 1998. Two percent of patients were younger than 40 years, and 38% were 70 years or older (Table 1); the median age was 66 years. Of these 1027 patients, 59% were men, 97% were white, and 1% were African American, a reflection of the ethnic composition of Mayo Clinic patients.
DISCUSSION
The age and sex distributions of the 1027 patients were similar to those of the 869 patients with multiple myeloma seen at the Mayo Clinic from 1960 to 19716 with respect to the median age and percentage of patients younger than 40 years. Only 1% were African American, but this rate is similar to the ethnic composition of Mayo Clinic patients. However, in the current study, 38% of patients were 70 years or older, compared with 23% in the earlier study. The incidence of multiple myeloma is much
REFERENCES (48)
- et al.
Total therapy with tandem transplants for newly diagnosed multiple myeloma
Blood
(1999) - et al.
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
Blood
(2000) - et al.
Hematopoiesis and cytokines: relevance to cancer and aging
Hematol Oncol Clin North Am
(2000) - et al.
Negative regulation of erythroblast maturation by Fas-L(+)/TRIAL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma
Blood
(2002) - et al.
Magnetic resonance imaging of the bone marrow in hematologic malignancies
Blood
(1997) - et al.
Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies
Mayo Clin Proc
(1987) - et al.
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma
Blood
(1988) - et al.
Prognostic factors in multiple myeloma
Hematol Oncol Clin North Am
(1999) - et al.
Plasmablastic morphology: an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trialE9486 report by the ECOG Myeloma Laboratory Group
Blood
(1998) - et al.
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma
Blood
(1996)
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
Blood
Current therapy for multiple myeloma
Mayo Clin Proc
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
Blood
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma
Blood
Multiple myeloma: advances in disease biology: therapeutic implications
Semin Hematol
Vital Statistics of the United States, 1988. Vol 2. Mortality, Part A
Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945
J Clin Oncol
Henry Bence Jones—physician, chemist, scientist and biographer: a man for all seasons
Br J Haematol
Multiple myeloma: an odyssey of discovery
Br J Haematol
Multiple-myeloma proteins III: the antigenic relationship of Bence Jones proteins to normal gamma-globulin and multiple-myeloma serum proteins
Cancer
Multiple myeloma: review of 869 cases
Mayo Clin Proc
Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation
Am J Hematol
Fever of unknown origin caused by multiple myeloma: a report of 9 cases
Arch Intern Med
Cited by (0)
This study was supported by grant CA62242 from the National Cancer Institute.